Akebia Therapeutics' Vafseo expansion may boost future growth despite Auryxia's exclusivity loss. Read why AKBA stock is rated a hold.

Akebia Therapeutics had a strong US launch of Vafseo and Q1 revenues signal robust demand, but near-term profitability remains uncertain. Read more on AKBA stock here.

He expects VAFSEO’s ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. Why Akebia ...

Vafseo has been gaining traction among dialysis organizations, and its launch is expected to counteract the generic impact on Akebia’s other product, Auryxia (ferric citrate), which targets ...

Vafseo has been gaining traction among dialysis organizations, and its launch is expected to counteract the generic impact on Akebia’s other product, Auryxia (ferric citrate), which targets ...

The financial results were driven by strong sales of Vafseo and Auryxia, with Vafseo generating $12 million in net revenues. Additionally, H.C. Wainwright initiated coverage of Akebia Therapeutics ...

The financial results were driven by strong sales of Vafseo and Auryxia, with Vafseo generating $12 million in net revenues. Additionally, H.C. Wainwright initiated coverage of Akebia Therapeutics ...

XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia ; Averoa submitted XOANACYL for UK approval via MHRA’ ...

Ferric citrate has been approved and is being commercialized in different regions: in the United States (US) under the brand name Auryxia® (ferric citrate) by Akebia Therapeutics, Inc.; in Japan ...